Nurix Therapeutics (NRIX) Receivables - Other (2020 - 2026)

Nurix Therapeutics (NRIX) has 7 years of Receivables - Other data on file, last reported at $1.9 million in Q2 2026.

• On a quarterly basis, Receivables - Other rose 11.76% year-over-year to $1.9 million in Q2 2026; TTM through May 2026 was $1.9 million, a 11.76% increase from a year earlier, with the FY2025 full-year figure at $1.5 million, changed 0.0% from the prior year.
• Receivables - Other for Q2 2026 stood at $1.9 million, down from $2.4 million in the prior quarter.
• Over the last five years, Receivables - Other for NRIX reached as high as $2.4 million in Q1 2026 and fell as low as $600000.0 in Q2 2024.
• Historically, Receivables - Other has averaged $1.3 million across 5 years, with a median of $1.1 million in 2022.
• Across the five-year window, Receivables - Other tumbled 78.0% in 2022 and jumped 183.33% in 2025, its largest moves.
• Year by year, Receivables - Other stood at $1.1 million in 2022, then dropped by 27.27% to $800000.0 in 2023, then jumped by 87.5% to $1.5 million in 2024, then changed by 0.0% to $1.5 million in 2025, then gained by 26.67% to $1.9 million in 2026.
• Per Business Quant data, the three most recent Receivables - Other figures were $1.9 million in Q2 2026, $2.4 million in Q1 2026, and $1.5 million in Q4 2025.